|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Colorado at Denver and Health Sciences Center |
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000331 |
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.
Condition | Intervention | Phase |
Heroin Dependence Opioid-Related Disorders |
Drug: Opioid-Related Disorders |
Phase II |
MedlinePlus related topics: | Heroin |
Drug Information available for: | Naloxone Naloxone hydrochloride Buprenorphine Buprenorphine hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind, Placebo Control |
Official Title: | Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age, and have no prior history of drug or alcohol abuse or dependence. Subjects must have had some minimal experience with opioids (e.g. at least two prior exposures)
Exclusion Criteria:
Individuals with evidence of an active DSM-IV Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.
United States, Colorado | |||||
University of Colorado Health Sciences Center | |||||
Denver, Colorado, United States, 80206 |
National Institute on Drug Abuse (NIDA) |
University of Colorado at Denver and Health Sciences Center |
Principal Investigator: | Leslie Amass, Ph.D. | University of Colorado at Denver and Health Sciences Center |
Study ID Numbers: | NIDA-11160-6, R01-11160-6 |
First Received: | September 20, 1999 |
Last Updated: | November 3, 2005 |
ClinicalTrials.gov Identifier: | NCT00000331 |
Health Authority: | United States: Federal Government |
|
|
|
|